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Objectives. We sought to evaluate the diagnostic and prognostic
value of cardiac troponin I (cTnI) in emergency department (ED)
patients with chest pain.
Background. Although cTnI has been shown to correlate with
an increased risk for complications in patients with unstable
angina, the prognostic significance of this assay in the heteroge-
neous population of patients who present to the ED with chest
pain is unclear.
Methods. cTnI and creatine kinase-MB fraction (CK-MB) mass
concentration were collected serially during the first 48 h from
onset of symptoms in 1,047 patients >230 years old admitted for
acute chest pain. Sensitivity, specificity and receiver operating
characteristic curves were calculated for cTnI and CK-MB col-
lected in the first 24 h.
Results. The sensitivity, specificity and positive predictive value
of cTnI for major cardiac events were 47%, 80% and 19%,
respectively. Among patients were who ruled out for myocardial
infarction, cTnI was elevated in 26% who had major cardiac
complications compared with 5% for CK-MB; the positive predic-
tive value for an abnormal cTnI result was 8%. Elevated cTnI in
the presence of ischemia on the electrocardiogram was associated
with an adjusted odds ratio of 1.8 (95% confidence interval 1.1 to
2.9) for major cardiac events within 72 h. Among patients without
a myocardial infarction or unstable angina, cTnI was not an
independent correlate of complications.
Conclusions. In patients presenting to the ED with acute chest
pain, cTnI was an independent predictor of major cardiac events.
However, the positive predictive value of an abnormal assay result
was not high in this heterogeneous cohort.
(J Am Coll Cardiol 1998;32:8–14)
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Identification of patients who present with acute chest pain at
high risk for major cardiac events is a common and difficult
challenge. Until recently, the initial evaluation of such patients
has relied on data from the history, physical examination and
electrocardiogram (ECG) (1–3). Investigations of creatine
kinase (CK) and CK-MB fraction (CK-MB) indicate that these
tests are of limited prognostic value in the initial evaluation
(4–7). Furthermore, among patients in whom acute myocar-
dial infarction has been excluded, CK-MB has not correlated
with subsequent major complications (8,9).
In recent years, considerable investigative interest has
focused on new markers of myocardial injury, especially on the
cardiac troponins. Previous studies with small sample sizes
have demonstrated the prognostic value of cardiac troponin I
(cTnI) for risk stratification in patients with unstable angina
and myocardial infarction (10–13). cTnI has also been studied
for the diagnosis of myocardial infarction (14–17).
Although these data suggest that cTnI is more sensitive and
specific than CK-MB and lactate dehydrogenase for detection
of myocardial damage at the cellular level (17,18), most clinical
studies have been restricted to high risk patients with unstable
angina or myocardial infarction (14–16). The diagnostic per-
formance of this assay in a lower risk, heterogeneous group of
patients with acute chest pain requires additional investigation,
in part because such a cohort provides a “real-life” test of the
assay’s specificity. Furthermore, because the complication rate
in a lower risk population is reduced, the positive predictive value
(PPV) of an abnormal test result can be expected to be lower than
that encountered in studies of higher risk patients. We therefore
undertook a prospective investigation of the diagnostic and
prognostic value of cTnI in .1,000 such patients. The findings
confirm the prognostic value of cTnI but suggest that its applica-
tion should be limited in low risk patient subsets.
Methods
Patients. Eligible patients included all 1,139 patients $30
years old who presented to the emergency department (ED)
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and were admitted to the Brigham and Women’s Hospital
between July 27, 1994 and June 30, 1995 with a chief complaint
of anterior, precordial or left lateral chest pain that could not
be explained by local trauma or abnormalities on the chest
roentgenogram. Patients had serial blood sampling for CK and
CK-MB according to a “rule-out myocardial infarction” pro-
tocol, and cTnI was measured in serum from these same
samples. Ninety-two patients were excluded because of incom-
plete cTnI or CK-MB data during the first 24 h; therefore,
1,047 patients (92%) were considered the study cohort.
Data collection. Data from the history, physical examina-
tion and ECG were recorded by the evaluating physician in the
ED or by a research nurse (G.P.-K., L.L.) according to the
previously described protocol of the Multicenter Chest Pain
Study (19,20). These data were recorded on a standardized
form that was part of the permanent medical record. The
person who completed the form had no knowledge of, and thus
could not be influenced by, the patient’s course after treatment
in the emergency room. Cardiac enzyme measurements were
obtained according to a standard “rule-out myocardial infarc-
tion protocol” that specified CK and CK-MB sampling every
8 h for 24 h. The charts of all admitted patients were reviewed
each day by a trained study nurse (G.P.-K., L.L.) who recorded
dates and times of cardiovascular procedures and complica-
tions, cardiac enzyme levels and diagnoses.
The same samples obtained for CK-MB determination in
the ED and after admission to the hospital were used for cTnI
assays. These data were not available to physicians who
managed the patients in the ED or after admission. The
investigators (T.H.L., P.A.J.) who classified patients and their
clinical outcomes or complications, or both, were blinded to
the results of this cardiac enzyme.
Total CK was assayed throughout this study on an ACA
discrete clinical analyzer (Du Pont). The upper reference
values were 218 and 266 U/liter for women and men, respec-
tively. A mass assay for CK-MB was performed, utilizing a
monoclonal antibody, with the Stratus instrument (Baxter
Diagnostic). The upper limit of reference was 5 ng/ml. Cardiac
troponin I was measured by an immunoassay procedure that
uses complementary monoclonal antibodies, as described by
Bodor et al. (14) and Zaninotto et al. (21). All analyses were
performed using the same Stratus instrument (DADE Inter-
national Inc.); the signal detection limit (smallest concentra-
tion that can be distinguished from zero) was 0.4 ng/ml, and the
upper reference limit for this assay was 1.5 ng/ml.
Diagnosis. A diagnosis of myocardial infarction was made if
any of the following criteria were present: 1) an absolute value
of CK-MB .5 ng/ml using the mass assay; 2) an ECG showing
development of pathologic Q waves (at least 0.04 s in duration)
and at least 25% decrease in the amplitude of the following R
wave compared with that of the ED ECG; 3) sudden cardiac
arrest in patients who died before it was possible to obtain
enzymatic confirmation of myocardial necrosis and if there
were no other explanation for the arrest; and 4) administration
of acute reperfusion therapy with intravenous thrombolytic
agents or primary angioplasty, if the patient had new ST
segment elevation that evolved over the next day, or if patients
undergoing primary angioplasty also had known occlusion or
subtotal occlusion of the artery presumed to be infarct related.
Patients who showed evolution of cardiac enzymes after the
performance of an invasive cardiac procedure were not con-
sidered to have had an acute myocardial infarction. All poten-
tial cases of acute myocardial infarction were reviewed by a
cardiologist (C.A.P., P.A.J.) blinded to cTnI data. Unstable
angina was diagnosed if the patient’s original chest pain
syndrome was either new or worse in frequency, severity or
duration than his or her chronic anginal syndrome and was
made by the senior clinician responsible for the patient.
The present study examined the relation between cardiac
markers obtained during the first 24 h and early cardiac events.
Therefore, only major cardiac events within 72 h after presen-
tation to the ED were included in the analyses. Major cardiac
events included cardiogenic shock or cardiac arrest, ventricular
tachycardia or ventricular fibrillation requiring defibrillation,
Mobitz II second-degree atrioventricular block requiring tem-
porary or permanent pacing, new complete heart block, use of
an intraaortic balloon pump, intubation, coronary artery by-
pass graft surgery and percutaneous transluminal coronary
angioplasty (PTCA). Analyses that included pulmonary edema
or severe congestive failure (n 5 16) among the major cardiac
events yielded similar findings but are not presented because
we considered the complications enumerated to be more
reliable in their diagnosis and more directly linked to myocar-
dial ischemia.
Statistical analysis. Sensitivity, specificity, PPV and nega-
tive predictive value (NPV) were calculated for 1) myocardial
infarction and 2) major cardiac events within the first 72 h for
the a) first sample and b) peak level of CK-MB and cTnI
detected during the first 24 h after presentation to the ED.
Only first samples that were collected ,3 h after presentation
to the ED were considered in the analyses of the diagnostic
performance of initial samples. Although cTnI and CK-MB
were serially collected, the peak measurements detected in the
first 24 h were used to calculate the performance of the cardiac
markers. Only CK-MB and cTnI samples that were obtained
before the first major event were included in analyses. Hence,
an abnormal test result obtained after an invasive cardiac
procedure had occurred was not included. Analysis of the
correlation of cTnI and major cardiac events was performed
Abbreviations and Acronyms
CK 5 creatine kinase
CK-MB 5 creatine kinase-MB fraction
cTnI 5 cardiac troponin I
ECG 5 electrocardiogram, electrocardiographic
ED 5 emergency department
NPV 5 negative predictive value
PPV 5 positive predictive value
PTCA 5 percutaneous transluminal coronary angioplasty
ROC 5 receiver operating characteristic
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for the entire cohort and in the subset of patients who were
ruled out for an acute myocardial infarction.
Sensitivity was defined as the number of patients with the
outcome and an abnormal test result divided by the number of
patients with the outcome. Specificity was defined as the
number of patients without the outcome and with a normal
result divided by the number of patients without the outcome.
PPV was defined as the number of patients with the outcome
and an abnormal test result divided by the number of patients
with an abnormal test. NPV was defined as the number of
patients without outcome and a normal test result divided by
all those with a normal test result.
Receiver operating characteristic (ROC) curves were con-
structed to compare the discriminative power of cardiac en-
zyme tests. Areas under the ROC curve and differences
between ROC curves were assessed as described by Hanley
and McNeil (22) and Metz (23). Differences between the
sensitivity and specificity of CK-MB and cTnI were calculated
with the McNemar test for correlated proportions. Multivari-
ate logistic regression analysis was used to assess the indepen-
dent predictor ability of cTnI and CK-MB for major cardiac
events after adjustment for clinical risk factors. A p value
,0.05 was considered statistically significant.
Results
Patients. The study cohort (n 5 1,047) had a mean (6SD)
age of 61 6 14 years and included a large proportion of women
and nonwhites (Table 1). Slightly more than half of the
patients described the quality of their pain as “pressure,” and
a minority had a previous history of myocardial infarction or
angina. The median time interval between onset of chest pain
and presentation to the ED was 8 h. The ED ECG was
interpreted as having new ischemic changes ($1-mm ST
segment elevation or new Q waves in two or more continuous
leads, ST segment depression or other new alterations believed
to be ischemic) in 27% of the study cohort. There was no
significant difference in clinical characteristics and outcomes
between the study cohort (n 5 1,047) and patients who were
admitted but excluded from the study because of missing cTnI
or CK-MB data (n 5 92).
Myocardial infarction was diagnosed in 142 patients (14%),
and 385 (37%) had a final diagnosis of unstable angina (Table
2). Ninety-four subjects (9%) experienced at least one major
cardiac event during the first 72 h after admission. Major
cardiac event rates were 26%, 15% and 0.2% among subsets of
patients with a diagnosis of myocardial infarction, unstable
angina or nonischemic chest pain, respectively. Only one major
cardiac complication occurred among the 520 patients without
a diagnosis of acute myocardial infarction or unstable angina.
cTnI and diagnosis of acute myocardial infarction (Table
3). Sensitivity, specificity, PPV and NPV for acute myocardial
infarction for peak cTnI and CK-MB during the first 24 h are
presented in Table 3. Elevated cTnI levels ($0.4 ng/ml) were
detected within 24 h of admission in 84% of the 142 patients
with a myocardial infarction. Patients with a final diagnosis of
myocardial infarction and a normal level of cTnI (n 5 23) were
predominantly patients with a small, non-Q wave myocardial
infarction (n 5 17). Among the patients with a myocardial
infarction and normal cTnI levels, one underwent coronary
artery bypass graft surgery, and four underwent PTCA during
the first 24 h after presentation to the ED. In these patients,
there may have been insufficient time for cTnI to increase to
abnormal levels because cTnI considered for analysis included
only those collected before the procedures. One patient with
ECG abnormalities consistent with a large acute myocardial
infarction had a cardiac arrest within the first hour after
presentation to the ED but had a normal cTnI level before the
acute episode.
The specificity of the cTnI assay using 0.4 ng/ml as the
threshold value was 87%; hence, 13% of patients without a
myocardial infarction in this cohort had increased levels of
cTnI. When a higher cutoff value of 1.5 ng/ml was used, the
specificity of this marker improved to 97% and was similar to
CK-MB. The NPV of cTnI for acute myocardial infarction
using thresholds of 0.4 and 1.5 ng/ml were 97% and 96%,
respectively.
Because the diagnosis of acute myocardial infarction was
Table 1. Clinical Characteristics of 1,047 Study Patients
Age (yr) 61 6 14
Men 521 (50%)
Race
White 641 (61%)
Black 246 (23%)
Hispanic 141 (14%)
Asian 13 (1%)
Other 5 (1%)
Cardiac risk factor
Hypertension 639 (61%)
Diabetes mellitus 249 (24%)
High cholesterol 462 (44%)
Family history 429 (41%)
Current smoking 225 (22%)
Radiation of chest pain to left arm, left shoulder, jaw
or neck
524 (51%)
Quality of chest pain (pressure) 585 (56%)
Chest pain worse than or similar to previous chest pain 442 (42%)
Time elapsed since onset of symptoms
,4 h 274 (32%)
4–12 h 196 (23%)
.12 h 392 (45%)
History of previous
Myocardial infarction 329 (31%)
Angina pectoris 492 (47%)
Cardiac catheterization 346 (33%)
Coronary angioplasty 150 (14%)
Coronary artery bypass graft surgery 152 (15%)
Rales on physical examination 169 (16%)
Electrocardiographic findings
Normal 251 (24%)
$1-mm ST segment elevation or depression or other
new ischemic change
284 (27%)
Other nonischemic alteration 512 (49%)
Data presented are mean value 6 SD or number (%) of patients.
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made by investigators who used CK-MB criteria, comparisons
of CK-MB and cTnI are difficult to perform in this data set.
When ROC analysis was used to compare the diagnostic
performance of cTnI and CK-MB for the diagnosis of acute
myocardial infarction, the area under the ROC curve for cTnI
(0.92) was significantly smaller than the area under the ROC
curve for CK-MB (0.97, p , 0.001).
Initial cTnI (Table 4). cTnI levels were obtained within 3 h
of presentation to the ED for 808 patients. The median time
interval between onset of chest pain and drawing of cTnI
samples was 8.8 h and was not different among patients with
distinct outcomes. For these initial determinations, the sensi-
tivity and specificity of cTnI for acute myocardial infarction
were 40% and 95%, respectively (Table 4). Seventy-nine
patients (10%) with initial samples experienced at least one
major cardiac event within 72 h, for which cTnI showed a
sensitivity and specificity of 18% and 91%, respectively.
Among 703 patients who were ruled out for myocardial
infarction, 52 (7%) had a major cardiac event within 72 h of
presentation to the ED. Of these 52 patients, 3 (6%) had
abnormal initial troponin results (Table 4). There was no
increase in relative risk for major cardiac complications asso-
ciated with the initial cTnI among patients who did not have an
acute myocardial infarction.
cTnI and major cardiac events (Table 5). The diagnostic
performance of peak cTnI and CK-MB obtained during the
first 24 h for major cardiac events within 72 h is shown in Table
5. Among 94 patients who had early major cardiac complica-
tions, elevated cTnI levels were detected in 44 patients (47%)
during the first 24 h. Elevated cTnI levels were also detected
among 20% of patients without major events.
Among non–myocardial infarction patients, 385 (43%) had
a final diagnosis of unstable angina and 520 (57%) other
diagnosis. Seventy-four patients (32%) with unstable angina
had abnormal levels of cTnI, and 40 (17%) with other diagno-
sis had elevated cTnI levels. No patient in the latter group
experienced a major cardiac event within 72 h from presenta-
tion to the ED. The sensitivity and specificity of elevated
troponin I levels in patients without a myocardial infarction for
a major cardiac event were 26% and 88%, respectively. The
PPV was 8% and the relative risk 2.6.
The sensitivity of peak CK-MB during the first 24 h for
major events was slightly lower than that for cTnI (38% vs.
47%, p 5 0.06). However, diagnostic test performance char-
acteristics were otherwise similar (area under the ROC curve
0.66 6 0.03 vs. 0.68 6 0.03, p 5 0.3). Among patients who were
Table 4. Diagnostic Performance of First Sample of Cardiac
Troponin I $0.4 ng/ml for Acute Myocardial Infarction and Major
Cardiac Events Within 72 h in 808 Study Patients
MI
Major Cardiac
Events
Major Cardiac
Events in Pts
With No MI
Sensitivity 40% (42/105) 18% (14/79) 6% (3/52)
Specificity 95% (664/703) 91% (663/731) 95% (615/651)
PPV 52% (42/81) 17% (14/81) 8% (3/39)
NPV 91% (664/727) 91% (663/727) 93% (615/664)
RR 5.9* 1.9* 1.0
*p , 0.05. Data presented are percent (number) of patients or relative risk
(RR). Other abbreviations as in Tables 2 and 3.
Table 2. Final Diagnosis and Major Cardiac Events* Within 72 h After Presentation to
Emergency Department
All Pts
(n 5 1,047)
Pts With MI
(n 5 142)
Pts With UA
(n 5 385)
Pts With No
MI or UA
(n 5 520)
$1 major cardiac events in 1st 72 h after
presentation to ED*
94 (9%) 37 (26%) 56 (15%) 1 (0.2%)
Cardiac arrest 7 (0.7%) 1 (0.7%) 5 (1.3%) 1 (0.2%)
High degree AV block 1 (0.1%) 0 1 (0.3%) 0
Intubation 5 (0.5%) 2 (1.4%) 3 (0.8%) 0
Intraaortic balloon pump 26 (2%) 17 (12%) 9 (6%) 0
Coronary revasc 80 (8%) 32 (23%) 48 (13%) 0
*Cardiogenic shock or cardiac arrest, ventricular tachycardia or ventricular fibrillation requiring defibrillation,
Mobitz II second-degree atrioventricular (AV) block requiring pacemaker, new complete heart block, use of intraaortic
balloon pump, coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. Data presented
are number (%) of patients (Pts). ED 5 emergency department; MI 5 myocardial infarction; UA 5 unstable angina.
Table 3. Diagnostic Performance of Cardiac Troponin I and
Creatine Kinase-MB Fraction Assays for Acute Myocardial
Infarction Relative to Peak Level in First 24 h After Presentation to
Emergency Department (1,047 study patients)
cTnI $0.4 ng/ml cTnI $1.5 ng/ml CK-MB $5.0 ng/ml
Sensitivity 84% (119/142)* 75% (106/142)* 96% (137/142)
Specificity 87% (791/905)* 97% (875/905) 97% (881/905)
PPV 51% (119/233) 78% (106/136) 85% (137/161)
NPV 97% (791/814) 96% (875/911) 99% (881/886)
Area under the
ROC curve
0.92 6 0.02* 0.97 6 0.01
*p , 0.001 versus creatine kinase-MB fraction (CK-MB). Data presented are
mean value 6 SD or percent (number) of patients. cTnI 5 cardiac troponin I;
NPV 5 negative predictive value; PPV 5 positive predictive value; ROC 5
receiver operating characteristic.
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ruled out for myocardial infarction, the sensitivity of peak
CK-MB was significantly lower than that for cTnI (5% vs. 26%,
p 5 0.001), but the overall performance was not different.
Multivariate analyses. By multivariate analyses, four clin-
ical variables were correlated with experiencing a major car-
diac event within 72 h: ECG ischemia, chest pain worse than
previous angina, history of PTCA and male gender. After
adjustment for these patient characteristics at presentation, an
elevated cTnI level during the first 24 h was significantly
associated with major cardiac events. Subjects were stratified
according to the presence of these independent predictors of
major complications (Table 6). Among patients with none of
these predictors present, an abnormal cTnI was not associated
with an increased risk for cardiac events. However, in the
presence of one or more predictors and no ECG ischemia,
patients with elevated cTnI levels had a twofold higher risk of
having an event than patients with normal cTnI levels. The
same findings were observed for patients with ECG ischemia.
Among patients who were ruled out for myocardial infarc-
tion, ECG ischemia at admission was the strongest predictor
for major event and an important effect modifier in the
association between cTnI and major events. When the other
variables were controlled, cTnI was not a significant predictor
in patients with a no ECG ischemia (odds ratio [OR] 0.7, 95%
confidence interval [CI] 0.2 to 2.7). Subjects with ECG isch-
emia and cTnI levels .0.4 ng/ml detected within 24 h had a
4.4-fold (95% CI 1.7 to 11.6) increase in the odds of an event
compared with subjects with normal cTnI levels. CK-MB levels
were also associated with major cardiac events (OR 1.1, 95%
CI 1.0 to 1.2, per unit increase); however, after adjustment for
clinical variables and cTnI, CK-MB was no longer correlated
with major cardiac events among patients without a myocardial
infarction.
Discussion
In the present study, we describe the diagnostic perfor-
mance characteristics of cTnI for myocardial infarction and
major cardiac events in a lower risk, heterogeneous cohort of
patients presenting with acute chest pain to the ED. In this
cohort, increased initial or peak cTnI levels during the first
24 h were associated with an increased risk for acute myocar-
dial infarction and major cardiac events. Nevertheless, the
PPV of an abnormal test result was lower than has been
described (17) in higher risk patient groups. Furthermore, a
negative test result was not a guarantee of a good prognosis:
Among 57 patients without acute myocardial infarction who
had major complications during the first 72 h, only 26% had
abnormal peak cTnI levels during the first day of observation.
Sensitivity of cTnI for myocardial infarction and major
cardiac events. These data are consistent with and extend
findings from previous research (10,17,24) that has identified
cTnI as a marker for myocardial injury potentially superior to
CK-MB. Although this test has been extensively evaluated in
patients with unstable angina and acute myocardial infarction,
there are few data on the performance of this assay in lower
risk, heterogeneous patients with acute chest pain. In patients
admitted to the coronary care unit, the sensitivity of this assay
for acute myocardial infarction has been nearly perfect (16).
In the present study, we also found excellent if a slightly
lower sensitivity (84%) for diagnosing myocardial infarction.
Whether these data reflect an inaccurate clinical diagnosis of
myocardial infarction or failure of cTnI to detect myocardial
injury is uncertain. cTnI assays with lower detection limits of
0.1 ng/ml have the theoretical potential to be more sensitive for
detecting myocardial injury. However, in studies conducted in
selected patients with myocardial infarction, results have been
similar to those that used assays with a higher detection limit
(16,25). The scarce data available do not allow conclusions on
whether differences in previous published results could be
attributed to differences in the assays currently used. Technol-
ogy continues to evolve, and improvements in the assay used to
measure cTnI may improve its sensitivity.
Value of early cTnI in the ED. cTnI is used in the ED by
some clinicians to guide triage decisions. However, in our
study, cTnI levels collected within the first 3 h of admission had
Table 5. Diagnostic Performance of Peak Cardiac Troponin I $0.4
ng/ml and Creatine Kinase-MB Fraction Mass $5.0 ng/ml for Major
Cardiac Events Within 72 h in Entire Cohort and in Patients Ruled
Out for Myocardial Infarction
All Pts Pts With No MI
cTnI CK-MB cTnI CK-MB
Sensitivity 47% (44/94) 38% (36/94) 26% (15/57) 5% (3/57)
Specificity 80% (763/953) 87% (827/953) 88% (749/848) 98% (827/848)
PPV 19% (44/234) 22% (36/162) 8% (3/38) 13% (3/24)
NPV 94% (763/813) 93% (827/885) 95% (749/791) 94% (827/881)
RR 3.1* 3.4* 2.6* 2.1*
*p , 0.05. Data presented are percent (number) of patients or relative risk
(RR). Other abbreviations as in Tables 2 and 3.
Table 6. Probability of Major Cardiac Events Within 72 h by
Presence of Independent Predictors* or Ischemia on Admission
Electrocardiogram and Peak Cardiac Troponin I Level in First 24 h
After Presentation to Emergency Department for All Patients
Major Cardiac Event
[% (no.) of pts]
RR
(95% CI)
No predictors
cTnI ,0.4 ng/ml 0.5% (1/217)
cTnI $0.4 ng/ml 3.7% (1/27) 8.0 (0.6–124)
$1 predictor and no ECG ischemia
cTnI ,0.4 ng/ml 6% (24/429)
cTnI $0.4 ng/ml 12% (11/90) 2.2 (1.1–4.3)
ECG ischemia
cTnI ,0.4 ng/ml 15% (25/167)
cTnI $0.4 ng/ml 27% (32/117) 1.8 (1.1–2.9)
*Male gender, chest pain worse than previous pain, previous coronary
angioplasty and electrocardiographic (ECG) ischemia ($1-mm ST segment
elevation, ST segment depression or new Q waves in two or more contiguous
leads or other new alterations believed to be ischemic). CI 5 confidence interval;
other abbreviations as in Tables 2 and 3.
12 POLANCZYK ET AL. JACC Vol. 32, No. 1
TROPONIN I IN ACUTE CHEST PAIN July 1998:8–14
a poor sensitivity for detecting myocardial infarction and
predicting major cardiac events. Single plasma levels of cTnI at
admission did not offer any additional information to clinical
and ECG data. These findings are consistent with those of
Mair et al. (17) who described a low (23%) early sensitivity of
cTnI for acute myocardial infarction in patients with chest pain
on admission to the emergency room. These data emphasize
that cTnI should not be relied on as the sole factor in deciding
whether to discharge patients home from the ED.
Specificity and false positive results of cTnI. The specific-
ity of cTnI for myocardial damage has been emphasized as one
of the advantages of this marker (26). In the present report, the
specificity of cTnI assay using a threshold value of 0.4 ng/ml
was 87% for myocardial infarction but improved to 97% using
the higher cutoff of 1.5 ng/ml. These findings are consistent
with previous studies of markers of myocardial injury. Such
false positive results have been interpreted as potential evi-
dence that patients, especially patients with unstable angina,
with elevated cTnI levels but without CK-MB elevations may
have a mild degree of myocardial injury. In our study, 60% of
false positive results were observed in patients with a clinical
diagnosis of unstable angina.
When considering false positive results in a heterogeneous
cohort of ED patients with acute chest pain, some of the
findings may reflect possible noncardiac causes of elevated
cTnI levels. This possibility is suggested by recent reports of
patients with cancer and severe rhabdomyolysis but without
evidence of cardiac disease in whom abnormal levels of cTnI
were described (27,28). In addition, there have been reports of
elevated cTnI levels in other cardiac syndromes, such as in
heart transplant recipients or patients with congestive heart
failure (29).
Clinical implications. The present data are consistent with
other studies (11,12) that have shown that cTnI can improve
risk stratification of patients with acute coronary syndromes.
Antman et al. (11) reported that cTnI provides useful prog-
nostic information and improves prediction of risk of death in
patients with unstable angina or non–Q wave myocardial
infarction. In lower risk group of patients with acute chest pain,
our data suggest that cTnI may be most useful in the subgroup
with ECG abnormalities consistent with ischemia, but its
benefit in patients with benign ECG findings remains uncer-
tain. Previous reports (30–32) have evaluated early or imme-
diate noninvasive tests, such as imaging studies or exercise
tests, to further stratify this low risk subgroup, and the results
have suggested that such tests may be helpful in risk stratifi-
cation of these patients.
Study limitations. The present data were obtained from a
large cohort of heterogeneous patients at a single urban
teaching hospital. In our study, the diagnosis of myocardial
infarction was made by reviewers who used CK-MB; hence,
cTnI was at a “disadvantage” in comparisons of diagnostic
performance with CK-MB for this end point. It is also possible
that false positive cTnI results were a reflection of myocardial
injury too subtle to be detected by the methods available to the
investigators or clinicians. Long-term follow-up will be re-
quired to understand the true meaning of a false positive cTnI
result. Nevertheless, the finding that major clinical complica-
tions occurred in some patients with normal cTnI levels during
the first 24 h emphasizes that clinicians cannot rely on any
single laboratory test, including cTnI.
Conclusions. These data expand our understanding of the
role of cTnI as a marker for myocardial ischemic syndromes.
Although the present study does not support the routine use of
cTnI as a diagnostic tool in the ED, the test showed a
significantly better performance than CK-MB mass assay for
predicting major cardiac events among patients who were
ruled out for myocardial infarction. In patients with a previous
PTCA, chest pain worse than previously diagnosed angina or
myocardial infarction and male gender and in those who have
ECG ischemia, the presence of abnormal cTnI levels supports
the need for intensive patient evaluation and monitoring.
Normal cTnI values do not necessarily guarantee a benign
course; patients with such values may be appropriate for
exercise testing before discharge. Future studies are needed to
determine the best strategy to approach patients presenting to
the ED with chest pain because only a minority of low risk
patients who develop major cardiac events will be identified by
cTnI assay.
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